Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Avidity Biosciences
|
2024 | |||
Avidity Biosciences Q4 2023 (press release only) |
Avidity Biosciences Q1 2024 (press release only) |
Avidity Biosciences Q2 2024 (press release only) |
|
Feb. 28, 2024 | May 9, 2024 | Aug. 8, 2024 | |
2023 | |||
Avidity Biosciences Q4 2022 |
Avidity Biosciences Q1 2023 |
Avidity Biosciences Q1 2023 |
Avidity Biosciences Q1 2023 |
Feb. 28, 2023 | May 9, 2023 | Aug. 8, 2023 | Nov. 8, 2023 |
2022 | |||
Avidity Biosciences Q4 2021 |
Avidity Biosciences Q1 2022 |
Avidity Biosciences Q2 2022 |
Avidity Biosciences Q3 2022 |
March 1, 2022 | May 10, 2022 | Aug. 9, 2022 | Nov. 8, 2022 |
2021 | |||
Avidity Biosciences Q4 2020 |
Avidity Biosciences Q1 2021 |
Avidity Biosciences Q2 2021 Press Release |
Avidity Biosciences Q3 2021 summary |
March 16, 2021 | May 12, 2021 | August 9, 2021 | November 9, 2021 |
Avidity Biosciences (RNA) is a preclinical-stage biotechnology company specializing in a novel RNA therapy platform, antibody oligonucleotide conjugates or AOCs, for diseases caused by genetic mutations.
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
ILMN |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
SAGE |
SANA |
SGEN |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers